[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337452-105":59,"doc-detail-337452-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","progress-in-oligometastatic-prostate-cancer-emerging-imaging-innovations-and-therapeutic-approaches","Progress in Oligometastatic Prostate Cancer - Emerging Imaging Innovations and Therapeutic Approaches","","Prostate cancer (PCa) shows marked heterogeneity, with a substantial share of patients developing metastatic disease. Oligometastatic PCa—defined by a limited number of metastatic lesions in specific anatomical sites—has come into focus through advanced imaging modalities. While standard management for metastatic PCa relies on systemic therapy, personalized strategies for oligometastatic PCa are evolving, including surgical and radiotherapeutic interventions. Key themes include biology, imaging performance, clinical evidence, lesion characterization challenges, and treatment options such as cytoreductive surgery, radiotherapy to primary tumors, and metastasis-directed therapy evaluated in ongoing trials.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/progress-in-oligometastatic-prostate-cancer-emerging-imaging-innovations-and-therapeutic-approaches/337452/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/progress-in-oligometastatic-prostate-cancer-emerging-imaging-innovations-and-therapeutic-approaches/337452.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-11","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is oligometastatic prostate cancer and why is it gaining attention?","Question",{"text":113,"@type":114},"Oligometastatic prostate cancer involves a limited number of metastatic lesions in specific anatomical locations. Growing interest stems from advancements in imaging modalities that improve detection and characterization.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does advanced imaging support diagnosis of oligometastatic PCa?",{"text":118,"@type":114},"Imaging is crucial for identifying and characterizing oligometastatic lesions. Techniques such as PSMA-PET are highlighted for strong efficacy.",{"name":120,"@type":111,"acceptedAnswer":121},"What treatment strategies are explored for oligometastatic PCa?",{"text":122,"@type":114},"Management strategies include cytoreductive surgery and radiotherapy directed at the primary tumor, as well as metastasis-directed therapy for recurrent lesions. Ongoing clinical trials evaluate their effectiveness.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},337452,1790140913,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","cancers   \nReview  \nProgress in Oligometastatic Prostate Cancer: Emerging Imaging Innovations and Therapeutic Approaches  \nRyo Oka, Takanobu Utsumi *, Takahide Noro, Yuta Suzuki, Shota Iijima, Yuka Sugizaki, Takatoshi Somoto, Seiji Kato, Takumi Endo, Naoto Kamiya and Hiroyoshi Suzuki  \nCitation: Oka, R.; Utsumi, T.; Noro, T.; Suzuki, Y.; Iijima, S.; Sugizaki, Y.; Somoto, T.; Kato, S.; Endo, T.; Kamiya, N.; et al. Progress in Oligometastatic Prostate Cancer: Emerging Imaging Innovations and Therapeutic Approaches. Cancers 2024, 16, 507 .  \n[https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)cancers16030507  \nAcademic Editors: Emmanuel  \nS. Antonarakis, Gail Risbridger, Tadahiko Shien, Yuzuru Niibe and Dai Sonoda  \nReceived: 30 November 2023  \nRevised: 13 January 2024  \nAccepted: 22 January 2024  \nPublished: 24 January 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \nDepartment of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi 285-8741, Chiba,  \nJapan; [ryou.oka@med.toho-u.ac.jp](ryou.oka@med.toho-u.ac.jp) (R.O.); [takahide.noro@med.toho-u.ac.jp](takahide.noro@med.toho-u.ac.jp) (T.N.);  \n[yuta.suzuki@med.toho-u.ac.jp](yuta.suzuki@med.toho-u.ac.jp) (Y.S.); [shouta.iijima@med.toho-u.ac.jp](shouta.iijima@med.toho-u.ac.jp) (S.I.); [yuuka.kizuki@med.toho-u.ac.jp](yuuka.kizuki@med.toho-u.ac.jp) (Y.S.);  \n[takatoshi.soumoto@med.toho-u.ac.jp](takatoshi.soumoto@med.toho-u.ac.jp) (T.S.); [seiji.katou@med.toho-u.ac.jp](seiji.katou@med.toho-u.ac.jp) (S.K.);  \n[takumi.endou@med.toho-u.ac.jp](takumi.endou@med.toho-u.ac.jp) (T.E.); [naoto.kamiya@med.toho-u.ac.jp](naoto.kamiya@med.toho-u.ac.jp) (N.K.);  \n[hiroyoshi.suzuki@med.toho-u.ac.jp](hiroyoshi.suzuki@med.toho-u.ac.jp) (H.S.)  \n* Correspondence: [takanobu.utsumi@med.toho-u.ac.jp](takanobu.utsumi@med.toho-u.ac.jp); Tel.: +81-43-462-8811  \nSimple Summary: In recent years, there has been growing interest in oligometastatic prostate cancer (PCa) . Unlike more widespread forms of the disease, oligometastatic PCa involves only a limited number of cancerous lesions in specific areas of the body. This review delves into the latest advancements in our understanding of oligometastatic PCa, including how it works on a biological level, the use of advanced imaging techniques to spot it, and the various treatment approaches being explored. For patients with this intermediate-stage cancer, there is hope on the horizon, as personalized treatments such as surgery and targeted radiation therapy are showing promise. The findings from ongoing research may ultimately lead to better outcomes for individuals facing this unique challenge, bridging the gap between localized and widespread PCa.  \nAbstract: Prostate cancer (PCa) exhibits a spectrum of heterogeneity, from indolent to highly aggressive forms, with approximately 10–20% of patients experiencing metastatic PCa. Oligometastatic PCa, characterized by a limited number of metastatic lesions in specific anatomical locations, has gained attention due to advanced imaging modalities. Although patients with metastatic PCa typically receive systemic therapy, personalized treatment approaches for oligometastatic PCa are emerging, including surgical and radiotherapeutic interventions. This comprehensive review explores the latest developments in the field of oligometastatic PCa, including its biological mechanisms, advanced imaging techniques, and relevant clinical studies. Oligometastatic PCa is distinct from widespread metastases and presents challenges in patient classification. Imaging plays a crucial role in identifying and characterizing oligometastatic lesions, with new techniques such as","cbCaifFYjrNtSpRs","https://ap.wps.com/l/cbCaifFYjrNtSpRs","pdf",486966,13,"English","# Introduction\n# Simple Summary\n# Abstract\n# Keywords\n# Clinical and Biological Background\n## Imaging Advances and Detection\n## Treatment Approaches and Clinical Trials","[{\"question\":\"What is oligometastatic prostate cancer and why is it gaining attention?\",\"answer\":\"Oligometastatic prostate cancer involves a limited number of metastatic lesions in specific anatomical locations. Growing interest stems from advancements in imaging modalities that improve detection and characterization.\"},{\"question\":\"How does advanced imaging support diagnosis of oligometastatic PCa?\",\"answer\":\"Imaging is crucial for identifying and characterizing oligometastatic lesions. Techniques such as PSMA-PET are highlighted for strong efficacy.\"},{\"question\":\"What treatment strategies are explored for oligometastatic PCa?\",\"answer\":\"Management strategies include cytoreductive surgery and radiotherapy directed at the primary tumor, as well as metastasis-directed therapy for recurrent lesions. Ongoing clinical trials evaluate their effectiveness.\"}]","Progress in Oligometastatic Prostate Cancer - Emerging Imaging Innovations and Therapeutic Approaches | PDF",1790019198,33,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/60699504037a87275783da4d54be7b27.webp",983,1390,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/31211193e7be0d3ce43eb6c8269fad7e.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/affefabbd4eedfe7c809293de59a508a.webp",981,1387,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3310d0524e9c4393c4ca3bb101f6ea94.webp",980,1385]